MARKET

CGTX

CGTX

COGNITION THERAPEUTICS INC
NASDAQ
0.6006
+0.0006
+0.10%
Pre Market: 0.6196 +0.019 +3.16% 04:58 11/20 EST
OPEN
0.6039
PREV CLOSE
0.6000
HIGH
0.6197
LOW
0.5915
VOLUME
27
TURNOVER
0
52 WEEK HIGH
1.810
52 WEEK LOW
0.5501
MARKET CAP
57.12M
P/E (TTM)
-3.4144
1D
5D
1M
3M
1Y
5Y
1D
Cognition Therapeutics: Zervimesine’s Favorable Profile and Phase 3 Dementia with Lewy Bodies Trial Support $3 Price Target
TipRanks · 23h ago
We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Simply Wall St · 1d ago
Weekly Report: what happened at CGTX last week (1109-1113)?
Weekly Report · 4d ago
Cognition Therapeutics Earnings Call Signals DLB Momentum
TipRanks · 5d ago
What Makes Cognition Therapeutics (CGTX) a New Buy Stock
NASDAQ · 11/10 19:43
Cognition Therapeutics: Buy Reiterated on Zervimesine’s Phase 3 Progress; $3 Price Target Unchanged
TipRanks · 11/09 12:15
Weekly Report: what happened at CGTX last week (1102-1106)?
Weekly Report · 11/09 09:44
Cognition's Q3 Loss Declines To $4 Mln As Phase 3 For Zervimesine In Dementia Set To Begin
NASDAQ · 11/07 14:26
More
About CGTX
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease. Its CT1812 and pipeline of sigma-2 modulators can regulate pathways that are impaired in these diseases for the treatment of degenerative diseases. Its lead product candidate, CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins. Its pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways. It is developing other product candidates in the area of synucleinopathies.

Webull offers Cognition Therapeutics Inc stock information, including NASDAQ: CGTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CGTX stock methods without spending real money on the virtual paper trading platform.